Nectar Lifesciences Chairman's Speech > Engineering - Heavy > Chairman's Speech from Nectar Lifesciences - BSE: 532649, NSE: NECLIFE

Nectar Lifesciences

BSE: 532649|NSE: NECLIFE|ISIN: INE023H01027|SECTOR: Pharmaceuticals
May 24, 16:00
-1.85 (-5.3%)
VOLUME 166,411
May 24, 15:55
-1.8 (-5.17%)
VOLUME 425,578
Chairman's Speech (Nectar Lifesciences) Year : Mar '07
Dear Shareholders.
 I am delighted to inform you that your company, in line with our
 objectives, has yet again recorded very consistent and vibrant
 performance during the financial year 2006-07. During the year 2006-07,
 your company achieved sales turnover of Rs. 46518.14 Lacs registering
 62.61% increase over the previous year (Rs.  28606.85 lacs). Income
 before interest and depreciation increased to Rs. 9139.65 lacs
 registering 89.59% increase over the previous year (Rs. 4820.81 lacs).
 The net profit increased to Rs. 4835.82 lacs registering 89.27%
 increase over the previous year (Rs 2555.01 lacs). Your Directors
 expect a consistent growth in companys performance in the years to
 The most remarkable feature of the performance of your company has been
 the quality of our performance particularly in exports.  During the
 previous year, distribution of sales was 67% domestic and 33% exports.
 This year exports have upsurged to 45% with domestic at 55%. We expect
 this trend to further accelerate more towards exports with an estimated
 60:40 split between exports & domestic in the next financial year.
 As a part of one of the fastest growing economies of the world i.e.
 India, our aspirations and aim is to be in sync & contribute that very
 little but significant part to Indias increasing global presence
 besides catering to one of most robust domestic consuming market of the
 One of the most significant aspect of this year has been marked
 improvement in performance of your company through ongoing expansion of
 the global business which includes presence in both the regulated
 markets like US, Europe & the most happening BRIC (Brazil, Russia,
 India & China) markets besides 35 other geographies of the world.
 This rapid growth of your company is greatly attributed to a tremendous
 amount of cohesion between the management team as well as dedication
 and exemplary hard work put in by a highly skilled team of
 officers/executives, work force and other stakeholders of the company.
 In the lifesciences segment, where India is a very significant player
 globally, it is extremely essential and important to be a highly
 integrated player to not only survive in highly competitive environment
 but also to continue to register a sustainable growth as your company
 has done over the last few years. In this respect, your company is
 optimally integrated backwardly through the active pharmaceuticals
 ingredients segment particularly Cephalosoprins which is the biggect
 segment of antibiotics/anti bacterials part of pharmaceuticals the
 world over.
 In terms of forward integration our plant at Baddi in Himachal Pradesh,
 India for Finished Dossage Forms (PDF) has already gone on stream. This
 is a state of the art PDF facility which is comprehensively compliant
 with the highly stringent requirements of regulatory bodies like US
 PDA, EDQM , MHRA, MCC, TGA etc to name a few. It has global capacities
 for both Orals & Steriles forms and it is to the credit of a highly
 motivated team in your company
 which has put together an excellent global sized facility in place in
 record time. This facility strategically positions your company in the
 CRAMS (Compact Research & Manufacturing Services) segment of
 Lifesciences in which India has registered the highest segmental growth
 in Lifesciences industry.
 Additionally as part of the horizontal expansion, your company has also
 set up Empty Hard Gelatin Capsules (EHGC) Facility in Baddi which also
 is one of the most modern and technologically advanced facility. This
 unit will be the only EHGC unit in Baddi catering captively to
 practically all major Indian pharma units which are located in and
 around Baddi, Paonta Saahib, Uttaranchal & other tax exempted zones.
 The unit has been already operationalised. We expect to expand this
 unit also to global scale with an eye on the highly lucrative exports
 As a part of our highly successful innovative diversification strategy,
 your company has emerged as one of the leading global players in
 phytochemicals & herbal products for Menthol Crystals, Flakes and
 various derivatives. Within a very short time in this financial year
 and in the next financial year you will appreciate extremely good and
 robust contributions from this very important and critical sector,
 which in a way is also related to pharmaceuticals. Your company is
 enhancing the capacities of phyto-chemicals to global levels which will
 contribute significantly to both the top and bottomline of the company
 in the comingyears.
 I take this opportunity to record my gratitude and appreciate
 tremendous work put in by one & all of your company right from the
 worker to the top management for their dedication and highly value
 added contributions which has collectively led to this robust
 performance of your company. I am confident that all the stake- holders
 of the company will continue to register even better performance in the
 forthcoming eventful year 2007-08 when we can come back to you with
 even better performance than this financial year.
 I also take this opportunity to thank all other strategic stake-
 holders like the financial institutions, investors, our bankers and
 others without whose help and continued support we would not be able to
 do what we have done. I am absolutely reassured and confident that we
 will not only continue to get this support from them but even exceed
 your expectations so as to enable the company to continue to perform
 even better.
Source :
Quick Links for nectarlifesciences
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.